Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 90009530

Next Previous
Drug Profile

JNJ 90009530

Alternative Names: Anti-CD20 CART cells; Anti-CD20 CART-transduced T cells - AbelZeta Pharma; Anti-CD20 chimeric antigen receptor T cell therapy - AbelZeta Pharma; C-CAR066; CAR-CD20 T cell therapy; CAR066; CAR066 CAR; CART20; CBM-C20.1; CBM-CD20 1; Genetically engineered lymphocyte therapy - AbelZeta Pharma; JNJ-90009530; JNJ-9530

Latest Information Update: 18 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer AbelZeta Pharma; Chinese PLA General Hospital; Institute of Hematology & Blood Diseases Hospital; Janssen Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B-cell lymphoma; Leukaemia
  • Phase I Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Dec 2023 AbelZeta receives IND approval from USFDA for JNJ 90009530 for diffuse large B-cell lymphoma
  • 12 Dec 2023 Pooled efficacy and adverse events data from phase I trials in non-Hodgkin's lymphoma released by AbelZeta Pharma
  • 09 Dec 2023 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top